Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
RTEL1
REST API REST API
Homo sapiens
RTEL1 is differentially expressed in 180 experiments: 89 organism parts: blood, heart, ... (87 more);, 153 disease states: normal, colon carcinoma, ... (151 more);, 49 cell types 225 cell lines 27 compound treatments and 67 other conditions.
Synonyms DKFZP434C013, bK3184A7.3, KIAA1088, RTEL, NHL, C20orf41
Search EB-eye ENSG00000026036
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-AFMX-5, E-MEXP-1251, E-MTAB-24, E-MTAB-25, ... (16 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-3860, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, ... (27 experiments)

Factor Value U/D Experiments
SW480
1
3
E-MEXP-1014, E-GEOD-2509, E-GEOD-18005, E-MTAB-37
HT1080
2
E-GEOD-20089, E-MTAB-37
BT474
2
E-MTAB-62, E-MEXP-440
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
HCC44
2
E-MTAB-62, E-GEOD-4342
MCF-10A
2
E-TABM-420, E-GEOD-14990
219 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-GEOD-13987, ... (26 experiments)

Factor Value U/D Experiments
macrophage
2
E-GEOD-22373, E-GEOD-5099
basophil
1
E-GEOD-3982
CD34+ hematopoietic progenitor cell
1
E-GEOD-19240
immortalized cell culture
1
E-GEOD-14990
M2 macrophage
1
E-GEOD-5099
neutrophil
1
E-GEOD-12662
43 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-1869, E-GEOD-1577, E-MTAB-62, ... (38 experiments)

Factor Value U/D Experiments
Huntington's disease
2
E-AFMX-6, E-GEOD-3790
acute promyelocytic leukemia
2
E-MTAB-62, E-GEOD-1729
uterine fibroid
2
E-MTAB-62, E-GEOD-7307
colon carcinoma
1
2
E-GEOD-3726, E-MTAB-62, E-MTAB-57
Ewings Sarcoma
1
E-MTAB-62
abscess
1
E-MTAB-62
147 more value(s).


Compound treatment

studied in E-GEOD-6907, E-GEOD-15205, E-GEOD-5824, E-GEOD-5099, E-GEOD-6462, ... (14 experiments)

Factor Value U/D Experiments
dimethyl sulfoxide
2
E-GEOD-6932, E-GEOD-5824
chloroguine
1
E-GEOD-5418
4-hydroxytamoxifen
1
1
E-MEXP-2241
ethanol
1
E-MEXP-2241
hydrogen peroxide
1
E-GEOD-5339
no estradiol
1
E-GEOD-20081
21 more value(s).


Age at diagnosis

studied in E-GEOD-3494

Factor Value U/D Experiments
93
1
1
E-GEOD-3494


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd4
studied in E-GEOD-22601

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21589, E-GEOD-16363 ... (5 experiments)

Clinical info
studied in E-MTAB-37, E-GEOD-6710, E-MEXP-1251, E-GEOD-21589, E-GEOD-16363 ... (5 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-20033, E-GEOD-6236, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-3325, E-GEOD-2509

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-MTAB-73

Genotype
studied in E-TABM-1029, E-GEOD-17476, E-GEOD-21750, E-MEXP-421, E-GEOD-22593, ... (8 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-5681, E-MEXP-2657, E-GEOD-20504 ... (5 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-TABM-666, E-GEOD-19519, E-GEOD-16363, ... (18 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12254, E-GEOD-9723, E-GEOD-6802

Labeling
studied in E-LGCL-5

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-19703, E-GEOD-1309, E-GEOD-21750

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-18791

RNAi
studied in E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-1857

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

Stimulation
studied in E-GEOD-11886, E-GEOD-11428

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-19246, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290

Tumor size
studied in E-GEOD-3494

Vehicle
studied in E-GEOD-5258

Processing time: 0.372 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM